Targeting mutant RAS in patient-derived colorectal cancer organoids by combinatorial drug screening
Colorectal cancer (CRC) organoids can be derived from almost all CRC patients and therefore capture the genetic diversity of this disease. We assembled a panel of CRC organoids carrying either wild-type or mutant RAS, as well as normal organoids and tumor organoids with a CRISPR-introduced oncogenic...
Main Authors: | Carla S Verissimo, René M Overmeer, Bas Ponsioen, Jarno Drost, Sander Mertens, Ingrid Verlaan-Klink, Bastiaan van Gerwen, Marieke van der Ven, Marc van de Wetering, David A Egan, René Bernards, Hans Clevers, Johannes L Bos, Hugo J Snippert |
---|---|
Format: | Article |
Language: | English |
Published: |
eLife Sciences Publications Ltd
2016-11-01
|
Series: | eLife |
Subjects: | |
Online Access: | https://elifesciences.org/articles/18489 |
Similar Items
-
Drug-repurposing screen on patient-derived organoids identifies therapy-induced vulnerability in KRAS-mutant colon cancer
by: Sander Mertens, et al.
Published: (2023-04-01) -
The Role of Wild-Type RAS in Oncogenic RAS Transformation
by: Erin Sheffels, et al.
Published: (2021-04-01) -
Suppression of the HBP Function Increases Pancreatic Cancer Cell Sensitivity to a Pan-RAS Inhibitor
by: Francesca Ricciardiello, et al.
Published: (2021-02-01) -
Targeting BRAF and RAS in Colorectal Cancer
by: Helene Bellio, et al.
Published: (2021-05-01) -
RAS oncogenes direct metastasis
by: Magda Spella, et al.
Published: (2017-09-01)